

## CONTENTS

---

|          |   |           |
|----------|---|-----------|
| <b>1</b> | <b>GENERAL INTRODUCTION</b>   | <b>1</b>  |
| 1.1      | Obesity as worldwide problem: tendencies, possible causes and viable approaches . . . . . | 1         |
| 1.1.1    | Short overview of current on obesity trends worldwide                                     | 1         |
| 1.1.2    | Limitations of epidemiological data . . . . .   | 4         |
| 1.1.3    | Genetics . . . . .  | 4         |
| 1.1.4    | Evolutionary predisposition towards obesity . . . . .                                     | 5         |
| 1.1.5    | Bacterial 'domination' . . . . .  | 5         |
| 1.1.6    | Diet and lifestyle interactions in obesity . . . . .                                      | 6         |
| 1.2      | Approaches to combat obesity . . . . .  | 6         |
| 1.2.1    | Use of weight-reducing drugs . . . . .  | 6         |
| 1.2.2    | Bariatric surgery . . . . .   | 7         |
| 1.3      | Understanding the central and peripheral control of food intake . . . . .                 | 7         |
| 1.3.1    | Central control of eating . . . . .   | 8         |
| 1.3.2    | Peripheral signals and gut peptides involved in energy homeostasis . . . . .              | 9         |
| 1.3.3    | Leptin action on the brain . . . . .  | 10        |
| 1.3.4    | Glucagon-like peptide-1 (GLP-1) . . . . .   | 12        |
| 1.3.5    | Role of PPG neurons and their possible regulators . . . . .                               | 14        |
| 1.4      | Aims of the thesis . . . . .  | 16        |
| 1.5      | References . . . . .  | 17        |
| <b>2</b> | <b>ROLE OF PPG NEURONS IN REGULATING ENERGY HOMEOSTASIS IN MICE</b>                       | <b>35</b> |
| 2.1      | Abstract . . . . .  | 35        |
| 2.2      | Introduction . . . . .  | 36        |
| 2.3      | Materials and Methods . . . . .   | 37        |
| 2.3.1    | Animals and housing . . . . .   | 37        |
| 2.3.2    | DIO studies . . . . .   | 38        |
| 2.3.3    | Surgeries . . . . .   | 38        |
| 2.3.4    | PPG LV-shPPG knockdown . . . . .  | 38        |
| 2.3.5    | DREADD activator / silencer virus injection . . . . .                                     | 39        |
| 2.3.6    | Leptin receptor antagonist (LRA) injection . . . . .                                      | 39        |
| 2.3.7    | Oral glucose tolerance test (OGTT) . . . . .  | 40        |

|        |   |    |
|--------|---|----|
| 2.3.8  | mRNA level quantification of other genes  | 40 |
| 2.3.9  | Mouse perfusion   | 41 |
| 2.3.10 | Immunohistochemical staining  | 41 |
| 2.3.11 | Phenomaster study   | 42 |
| 2.3.12 | Statistical analysis  | 42 |
| 2.4    | Results   | 42 |
| 2.4.1  | HFD exposure increases central PPG mRNA expression in mice  | 42 |
| 2.4.2  | Leptin signalling deficiency increases central PPG mRNA expression in mice  | 44 |
| 2.4.3  | Chronic LRA injection into the 4th ventricle triggers BW loss   | 44 |
| 2.4.4  | PPG mRNA knockdown decreases FI and ameliorates BW gain in DIO mice   | 46 |
| 2.4.5  | PPG mRNA knockdown reduces hypothalamic NPY expression  | 46 |
| 2.4.6  | PPG mRNA knockdown does not affect PC enzyme levels in NTS  | 46 |
| 2.4.7  | Acute PPG neuronal activation and silencing using hM3Dq and hM4Di DREADD has opposite effects on food intake                | 49 |
| 2.4.8  | Chronic PPG neuronal activation and silencing with hM3D1 and hM4Di DREADD increases and decreases body weight, respectively | 51 |
| 2.5    | Discussion  | 51 |
| 2.6    | References  | 59 |
| 3      | INTESTINAL LYMPH AS A READOUT OF MEAL-INDUCED GLP-1 RELEASE   | 65 |
| 3.1    | Abstract  | 65 |
| 3.2    | Introduction  | 66 |
| 3.3    | Materials and Methods   | 67 |
| 3.3.1  | Catheter maintenance  | 69 |
| 3.3.2  | Lymph and blood sampling in relation to test meal with or without IP GLP-1 injection  | 70 |
| 3.3.3  | GLP-1 and insulin measurements  | 71 |
| 3.3.4  | Glucose and TG measurements   | 71 |
| 3.3.5  | DPP-IV activity assay   | 71 |
| 3.3.6  | Data analysis   | 72 |
| 3.4    | Results   | 72 |

|       |  |     |
|-------|--|-----|
| 3.4.1 | The HFD and LFD test meals increased MLD lymph and HPV plasma GLP-1 concentrations                               | 72  |
| 3.4.2 | IP GLP-1 injections increased MLD lymph and HPV plasma GLP-1 concentrations independent of test meal fat content | 74  |
| 3.4.3 | Insulin, glucose and fat metabolites showed similar profiles in MLD lymph and HPV plasma                         | 77  |
| 3.4.4 | DPP-IV activity was higher in HPV plasma compared to MLD lymph   | 80  |
| 3.5   | Discussion   | 81  |
| 3.6   | References   | 86  |
| 4     | GENERAL DISCUSSION   | 91  |
| 4.1   | Overview of the main findings  | 91  |
| 4.2   | Centrally and peripherally produced GLP-1  | 92  |
| 4.2.1 | Do peripheral and central GLP-1 have different roles?  | 92  |
| 4.2.2 | Possible mechanism of PPG upregulation   | 93  |
| 4.2.3 | Can PPG KD prevent DIO?  | 95  |
| 4.2.4 | Species differences  | 96  |
| 4.3   | Final remarks  | 97  |
| 4.4   | References   | 98  |
| A     | APPENDIX   | 101 |